Longeveron (LGVN) Set to Release Quarterly Earnings on Tuesday

Longeveron (NASDAQ:LGVN) is expected to release its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect the company to announce earnings of ($1.95) per share and revenue of $0.56 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:30 PM ET.

Longeveron (NASDAQ:LGVN) last issued its earnings results on Wednesday, August 12th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.75) by $1.56. Longeveron had a negative return on equity of 223.19% and a negative net margin of 1,977.59%. The company had revenue of $0.29 million for the quarter, compared to analyst estimates of $0.33 million.

Longeveron Trading Up 0.3%

NASDAQ LGVN opened at $1.60 on Tuesday. The company has a fifty day simple moving average of $4.41 and a 200 day simple moving average of $6.69. Longeveron has a 12-month low of $1.31 and a 12-month high of $12.30. The company has a market cap of $5.12 million, a P/E ratio of -0.16 and a beta of -0.19.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Weiss Ratings lowered shares of Longeveron from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, September 8th. Wall Street Zen downgraded shares of Longeveron from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $80.00.

Longeveron Company Profile

Longeveron Inc is a clinical-stage biotechnology company focused on developing regenerative medicines for serious and life-threatening conditions. The company’s research centers on cell-based therapies intended to support tissue repair, reduce harmful inflammation and promote the body’s natural healing processes.

Longeveron’s lead investigational product is Lomecel-B, an allogeneic cell therapy derived from bone marrow obtained from healthy adult donors. The company has evaluated Lomecel-B in clinical programs addressing hypoplastic left heart syndrome, a rare congenital heart defect in infants, as well as Alzheimer’s disease and aging-related frailty.